References
- Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094–1108. doi:10.1016/S0140-6736(15)00130-026354523
- Gao Y, Liu T, Huang Y. MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins. FEBS letters. 2015;589(2):207–214. doi:10.1016/j.febslet.2014.12.00225528443
- Gao Y, Liu T, Cheng W, Wang H. Isolation and characterization of proliferative, migratory and multidrug-resistant endometrial carcinoma-initiating cells from human type II endometrial carcinoma cell lines. Oncol Rep. 2012;28(2):527–532. doi:10.3892/or.2012.180722581025
- Dowdy SC, Glaser GE. Adjuvant therapy for women with high-risk endometrial carcinoma. Lancet Oncol. 2018;19(3):268–269. doi:10.1016/S1470-2045(18)30091-329449190
- Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–e258. doi:10.1016/S1470-2045(12)70073-622652233
- Pan Z, Shi Z, Wei H, et al. Magnetofection based on superparamagnetic iron oxide nanoparticles weakens glioma stem cell proliferation and invasion by mediating high expression of microRNA-374a. J Cancer. 2016;7(11):1487–1496. doi:10.7150/jca.1551527471565
- Liu T, Zhang H, Zheng J, et al. SPION-mediated miR-141 promotes the differentiation of HuAESCs into dopaminergic neuron-like cells via suppressing lncRNA-HOTAIR. J Cell Mol Med. 2018;22(4):2299–2310. doi:10.1111/jcmm.1351229411538
- Fang K, Liu P, Dong S, et al. Magnetofection based on superparamagnetic iron oxide nanoparticle-mediated low lncRNA HOTAIR expression decreases the proliferation and invasion of glioma stem cells. Int J Oncol. 2016;49(2):509–518. doi:10.3892/ijo.2016.357127277755
- Zhang H, Zheng J, Lin J, et al. miR-758 mediates oxLDL-dependent vascular endothelial cell damage by suppressing the succinate receptor SUCNR1. Gene. 2018;663:1–8. doi:10.1016/j.gene.2018.04.02929660520
- Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279(11):2047–2059. doi:10.1111/j.1742-4658.2012.08589.x22498306
- Vargas SL, Toma I, Kang JJ, Meer EJ, Peti-Peterdi J. Activation of the succinate receptor GPR91 in macula densa cells causes renin release. J Am Soc Nephrol. 2009;20(5):1002–1011. doi:10.1681/ASN.200807074019389848
- Mu X, Zhao T, Xu C, et al. Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget. 2017;8(8):13174–13185. doi:10.18632/oncotarget.1448528061458
- Littlewood-Evans A, Sarret S, Apfel V, et al. GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. J Exp Med. 2016;213(9):1655–1662. doi:10.1084/jem.2016006127481132
- He W, Miao FJ, Lin DC, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature. 2004;429(6988):188–193. doi:10.1038/nature0248815141213
- Favret S, Binet F, Lapalme E, et al. Deficiency in the metabolite receptor SUCNR1 (GPR91) leads to outer retinal lesions. Aging (Albany NY). 2013;5(6):427–444. doi:10.18632/aging.10056323833031
- de Castro Fonseca M, Aguiar CJ, Da Rocha Franco JA, Gingold RN, Leite MF. GPR91: expanding the frontiers of Krebs cycle intermediates. Cell Commun Signal. 2016;14:3. doi:10.1186/s12964-016-0126-126759054
- Aguiar CJ, Rocha-Franco JA, Sousa PA, et al. Succinate causes pathological cardiomyocyte hypertrophy through GPR91 activation. Cell Commun Signal. 2014;12:78. doi:10.1186/1478-811X-12-225539979
- Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature. 2013;496(7444):238–242. doi:10.1038/nature1198623535595
- Mills E, O‘Neill LA. Succinate: a metabolic signal in inflammation. Trends Cell Biol. 2014;24(5):313–320. doi:10.1016/j.tcb.2013.11.00824361092